← Back to patent-cliff list
RNK-08954
Tier C — Watch / tradeRNK-08954
-
Originator
-
First approval
-
Expiry (public)
No sales data
Peak sales
Small molecule
Type
Targets：KRAS G12D
Indications (approved)：Female reproductive system cancer, Solid tumour, Pancreatic cancer, 胰腺导管癌
Regional status
US
-
EU
-
China
Phase II
2024-11-08
Japan
-
Synthetic routes & intermediates
Routes not yet onboarded — the daily pipeline enriches by priority (approved small molecules first); this page updates automatically.
Frequently asked questions
What are the approved indications of RNK-08954?
Approved indications include: Female reproductive system cancer, Solid tumour, Pancreatic cancer, 胰腺导管癌.
When does the RNK-08954 patent expire?
No public expiry year is available for RNK-08954 yet; this page updates once verified.
How do I get a quote for RNK-08954 intermediates?
Open the CAS profile of the target intermediate from this page, or submit an RFQ directly — the CAS enters the matching flow automatically and the supply network responds with quotes.
Source: cross-verified data (structured fields only) · 2026-10-01